Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A JAMA review revealed that only 26% of pediatric ABRS patients treated with placebo required subsequent antibiotic therapy, prompting questions about current guidelines recommending first-line antibiotic use in children with sinusitis.
Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.
Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.